Skip to content

Anabolic Steroids for Nutritional Rehabilitation of Critically Ill Patients

The Efficacy of Anabolic Steroids for the Nutritional Rehabilitation of Critically Ill Patients

Status
Terminated
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00242463
Enrollment
20
Registered
2005-10-20
Start date
2005-10-31
Completion date
2007-10-31
Last updated
2011-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical Illness, Malnutrition

Keywords

malnutrition, anabolic steroids, intensive care unit, rehabilitation

Brief summary

This prospective, double-blinded study will determine the feasibility of determining the efficacy of a weekly intramuscular injection of nandrolone (an anabolic steroid) in malnourished ICU patients.The data from this study will also enable us to prepare a future grant proposal with a calculated sample size necessary to demonstrate an improvement in clinical outcome.

Detailed description

Critically ill patients are particularly prone to excessive catabolism using skeletal muscle as the primary substrate as a result of maladaptation to critical illness. Ultimately, critical illness leads to a significant loss of lean body mass (LBM). For example, a 40% loss of LBM is associated with a 100% mortality. Anabolic steroids have been studied and have been shown to improve nutrition in select malnourished patient groups, however, the majority of these studies were not well designed or consisted of small sample sizes. Our hypothesis is anabolic steroid administration will result in an augmentation of positive nitrogen balance and LBM. This increase in LBM will result in liberation from mechanical ventilation sooner than the placebo group and will result in discharge from the ICU sooner, and as a result, a reduction in morbidity (nosocomial infections) and possibly mortality. All moderately to severly malnourished ICU patients who have an anticipated stay in ICU \> 10 days, will be randomized to receive nandrolone (25 mg-females, 50 mg;males) once weekly for six weeks or placebo. All patients will receive a standard enteral nutritional regimen. Patients will be monitored for assessment of nitrogen balance, lean body mass, and length of time spent on ventilator, in ICU and in HOSP, and incidence of infections.Lean body mass will be measured using a bioimpedance analyzer.

Interventions

DRUGNandrolone (anabolic steroid)
DRUGPlacebo

Sponsors

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. anticipated length of stay in ICU \>10 days 2. moderate to severe malnutrition 3. patient tolerating enteral feeds

Exclusion criteria

1. age \< 18 yrs 2. known allergy to nandrolone 3. women of child bearing age with positive pregnancy test 4. contraindications to intramuscular injections ie anticoagulation 5. renal failure requiring renal replacement therapy 6. patients with breast or prostate cancer -

Design outcomes

Primary

MeasureTime frame
Nitrogen Balance

Secondary

MeasureTime frame
Lean body mass
serum prealbumin
length of stay on ventilator, in ICU, in HOSPITAL
infectious complications
outcome (mortality)

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026